Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125262 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL3413225 | 0.92 | ALDH1A1 (0.57) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL6378583 | 0.89 | ALDH1A1 (0.54) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL6378879 | 0.88 | APOBEC3A (0.40) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9191601 | 0.86 | ALDH1A1 (0.51) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9019803 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9197596 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL2437269 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL11249744 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SLC1A1CA1CA2CA7 | |
| SCHEMBL9207169 | 0.83 | ALDH1A1 (0.49) | ALDH1A1SLC1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102462-A1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | NESTOR JOHN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-20020042424-A1 | 2- (2-amino-1, 6-dihydro-6 -oxo-purin-9 -yl) methoxy-1, 3 -propanediol derivative | ROCHE PALO ALTO LLC | 2002-04-11 | — | — | US | disclosed |
| US-6083953-A | Treating herpes simplex virus or cytomegalovirus infections; valganciclovir hydrochloride in crystalline form; antiviral; oral administration | SYNTEX (U.S.A.) INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0694547-B1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivatives | HOFFMANN LA ROCHE (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5856481-A | Synthesis of antiviral agent valganciclovir (2-(2-amino-1,6-dihydro6-oxo-purin-9-yl)methoxy-3-hydroxy-1-propanyl-L-valinate) or salts via deprotection and salt formation | SYNTEX (U.S.A.) INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5840891-A | VIRICIDES WITH IMPROVED ABSORPTION | SYNTEX (U.S.A.) INC. (US) | 1998-11-24 | — | — | US | disclosed |
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0694547-A2 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | F. Hoffmann-La Roche AG (CH) | 1996-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042424-A1 | 2- (2-amino-1, 6-dihydro-6 -oxo-purin-9 -yl) methoxy-1, 3 -propanediol derivative | DPP7, PURB, EIF2AK2 | ALDH1A1 919/4885SLC1A1 1029/4885CA1 4809/4885 |
| US-20040102462-A1 | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | DPP7, PURB, EIF2AK2 | ALDH1A1 919/4885SLC1A1 1029/4885CA1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.